| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 84 | 2024 | 2474 | 12.560 |
Why?
|
| Antineoplastic Agents | 92 | 2023 | 14678 | 4.130 |
Why?
|
| Apoptosis | 69 | 2023 | 7847 | 4.030 |
Why?
|
| Arabinonucleosides | 37 | 2022 | 458 | 3.930 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 8 | 2016 | 45 | 2.940 |
Why?
|
| 2-Chloroadenosine | 13 | 2023 | 39 | 2.880 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 18 | 2023 | 289 | 2.880 |
Why?
|
| Purines | 11 | 2017 | 279 | 2.780 |
Why?
|
| Vidarabine | 43 | 2021 | 1383 | 2.600 |
Why?
|
| Multiple Myeloma | 25 | 2017 | 2321 | 2.590 |
Why?
|
| Lymphoma, Mantle-Cell | 10 | 2021 | 746 | 2.590 |
Why?
|
| Protein Kinase Inhibitors | 23 | 2024 | 4956 | 2.520 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 22 | 2023 | 1547 | 2.390 |
Why?
|
| Piperidines | 20 | 2024 | 1089 | 2.280 |
Why?
|
| Cytarabine | 47 | 2018 | 2014 | 2.130 |
Why?
|
| Antimetabolites, Antineoplastic | 25 | 2015 | 1345 | 2.050 |
Why?
|
| Hydrazones | 4 | 2016 | 43 | 2.000 |
Why?
|
| Pyrimidines | 17 | 2024 | 3666 | 1.990 |
Why?
|
| Adenine | 16 | 2024 | 667 | 1.990 |
Why?
|
| Pyrazoles | 13 | 2024 | 1542 | 1.880 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2021 | 16593 | 1.860 |
Why?
|
| Leukemia | 21 | 2020 | 1720 | 1.750 |
Why?
|
| Adenosine | 9 | 2012 | 300 | 1.730 |
Why?
|
| Adenosine Triphosphate | 20 | 2019 | 594 | 1.710 |
Why?
|
| Isoquinolines | 4 | 2017 | 126 | 1.700 |
Why?
|
| Purine Nucleosides | 10 | 2013 | 52 | 1.680 |
Why?
|
| Purine-Nucleoside Phosphorylase | 8 | 2010 | 51 | 1.670 |
Why?
|
| Pyrimidinones | 8 | 2013 | 317 | 1.610 |
Why?
|
| Sulfonamides | 13 | 2021 | 1919 | 1.540 |
Why?
|
| Tumor Cells, Cultured | 39 | 2019 | 5834 | 1.460 |
Why?
|
| Piperazines | 10 | 2020 | 2153 | 1.450 |
Why?
|
| Proteomics | 7 | 2024 | 1435 | 1.430 |
Why?
|
| Lymphocytes | 17 | 2019 | 1269 | 1.400 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2021 | 435 | 1.370 |
Why?
|
| Quinazolinones | 4 | 2017 | 53 | 1.350 |
Why?
|
| Pyridazines | 5 | 2013 | 319 | 1.350 |
Why?
|
| Deoxyadenosines | 4 | 2017 | 43 | 1.350 |
Why?
|
| Cell Line, Tumor | 47 | 2023 | 14864 | 1.340 |
Why?
|
| Humans | 260 | 2024 | 270856 | 1.320 |
Why?
|
| Signal Transduction | 27 | 2022 | 12205 | 1.320 |
Why?
|
| Deoxycytidine | 16 | 2007 | 1377 | 1.310 |
Why?
|
| Proto-Oncogene Proteins c-met | 7 | 2017 | 429 | 1.290 |
Why?
|
| Leukemia, Myeloid, Acute | 39 | 2023 | 7240 | 1.280 |
Why?
|
| Gene Expression Regulation, Leukemic | 6 | 2020 | 582 | 1.270 |
Why?
|
| Caspases | 11 | 2016 | 698 | 1.260 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 9 | 2021 | 996 | 1.250 |
Why?
|
| Adenine Nucleotides | 19 | 2017 | 365 | 1.240 |
Why?
|
| Cell Survival | 21 | 2019 | 3081 | 1.200 |
Why?
|
| Arabinonucleotides | 17 | 2008 | 71 | 1.150 |
Why?
|
| Stromal Cells | 8 | 2017 | 840 | 1.140 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2017 | 2618 | 1.130 |
Why?
|
| Bone Marrow Cells | 7 | 2019 | 985 | 1.110 |
Why?
|
| Imidazoles | 5 | 2013 | 1059 | 1.100 |
Why?
|
| Biphenyl Compounds | 6 | 2022 | 192 | 1.080 |
Why?
|
| Transcription, Genetic | 16 | 2013 | 3415 | 1.050 |
Why?
|
| Primary Cell Culture | 4 | 2020 | 203 | 1.050 |
Why?
|
| Gossypol | 3 | 2012 | 28 | 1.040 |
Why?
|
| Drug Screening Assays, Antitumor | 12 | 2020 | 573 | 1.040 |
Why?
|
| Nitrogen Mustard Compounds | 5 | 2018 | 74 | 1.040 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 2022 | 174 | 1.030 |
Why?
|
| Dose-Response Relationship, Drug | 29 | 2019 | 5105 | 1.020 |
Why?
|
| Reactive Oxygen Species | 6 | 2020 | 1011 | 1.010 |
Why?
|
| Bendamustine Hydrochloride | 6 | 2017 | 122 | 0.980 |
Why?
|
| Protein Biosynthesis | 6 | 2016 | 1037 | 0.980 |
Why?
|
| Prodrugs | 8 | 2014 | 226 | 0.960 |
Why?
|
| Phosphorylation | 29 | 2021 | 4985 | 0.960 |
Why?
|
| Ribonucleotide Reductases | 6 | 2013 | 48 | 0.930 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 18 | 2007 | 75 | 0.910 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2016 | 195 | 0.880 |
Why?
|
| Enzyme Inhibitors | 9 | 2023 | 1984 | 0.880 |
Why?
|
| Pyrazines | 3 | 2017 | 524 | 0.880 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2022 | 2899 | 0.860 |
Why?
|
| Oxidative Phosphorylation | 4 | 2021 | 267 | 0.840 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2023 | 623 | 0.840 |
Why?
|
| Animals | 63 | 2024 | 62759 | 0.820 |
Why?
|
| Autophagy | 5 | 2017 | 920 | 0.810 |
Why?
|
| B-Lymphocytes | 6 | 2020 | 1424 | 0.800 |
Why?
|
| RNA, Messenger | 21 | 2016 | 6483 | 0.800 |
Why?
|
| Cell Separation | 4 | 2019 | 616 | 0.790 |
Why?
|
| Glycolysis | 4 | 2019 | 533 | 0.790 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 2984 | 0.790 |
Why?
|
| Drug Resistance, Neoplasm | 23 | 2017 | 5411 | 0.790 |
Why?
|
| T-Lymphocytes | 12 | 2023 | 3928 | 0.790 |
Why?
|
| RNA, Neoplasm | 10 | 2012 | 811 | 0.760 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 11 | 2014 | 2633 | 0.750 |
Why?
|
| Proteome | 4 | 2024 | 572 | 0.750 |
Why?
|
| Ionophores | 1 | 2020 | 24 | 0.740 |
Why?
|
| Ataxia Telangiectasia | 1 | 2021 | 62 | 0.730 |
Why?
|
| Drug Synergism | 13 | 2020 | 1369 | 0.730 |
Why?
|
| Flow Cytometry | 10 | 2019 | 3083 | 0.730 |
Why?
|
| Guanosine Triphosphate | 9 | 2008 | 106 | 0.710 |
Why?
|
| Cell Proliferation | 20 | 2021 | 7294 | 0.700 |
Why?
|
| Thiazolidines | 2 | 2018 | 15 | 0.700 |
Why?
|
| Spiro Compounds | 1 | 2020 | 59 | 0.690 |
Why?
|
| Receptors, Growth Factor | 3 | 2008 | 160 | 0.680 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2016 | 2093 | 0.680 |
Why?
|
| Naphthalenes | 1 | 2020 | 84 | 0.670 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.660 |
Why?
|
| Polynucleotide Adenylyltransferase | 2 | 2009 | 13 | 0.650 |
Why?
|
| Leukocytes, Mononuclear | 6 | 2020 | 719 | 0.650 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2019 | 3653 | 0.640 |
Why?
|
| Mitochondria | 6 | 2020 | 1318 | 0.640 |
Why?
|
| Mice | 29 | 2024 | 35990 | 0.640 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2016 | 1571 | 0.630 |
Why?
|
| Heat-Shock Proteins | 2 | 2011 | 340 | 0.630 |
Why?
|
| Pyrrolidinones | 2 | 2017 | 62 | 0.630 |
Why?
|
| Caspase 3 | 4 | 2016 | 483 | 0.630 |
Why?
|
| Drug Design | 4 | 2018 | 378 | 0.620 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 2 | 2017 | 103 | 0.620 |
Why?
|
| Neoplasms | 22 | 2018 | 15849 | 0.610 |
Why?
|
| Oxidative Stress | 4 | 2020 | 1158 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2019 | 9078 | 0.610 |
Why?
|
| Coculture Techniques | 7 | 2019 | 635 | 0.600 |
Why?
|
| Zinc | 2 | 2016 | 197 | 0.600 |
Why?
|
| Biological Assay | 1 | 2019 | 182 | 0.590 |
Why?
|
| Lymphoma, B-Cell | 2 | 2016 | 935 | 0.590 |
Why?
|
| Drug Evaluation, Preclinical | 8 | 2016 | 504 | 0.590 |
Why?
|
| Cell Cycle | 16 | 2016 | 2151 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 3657 | 0.580 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2017 | 405 | 0.580 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 2006 | 72 | 0.580 |
Why?
|
| Hematologic Neoplasms | 10 | 2018 | 1955 | 0.570 |
Why?
|
| Benzamides | 4 | 2017 | 1883 | 0.560 |
Why?
|
| Oligopeptides | 2 | 2016 | 452 | 0.550 |
Why?
|
| DNA Damage | 8 | 2020 | 1980 | 0.550 |
Why?
|
| Cell Death | 10 | 2014 | 689 | 0.550 |
Why?
|
| RNA | 8 | 2016 | 1067 | 0.550 |
Why?
|
| Vidarabine Phosphate | 7 | 2002 | 50 | 0.540 |
Why?
|
| Caveolin 1 | 1 | 2017 | 204 | 0.540 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2015 | 685 | 0.520 |
Why?
|
| Energy Metabolism | 4 | 2019 | 1005 | 0.520 |
Why?
|
| Transcriptome | 1 | 2024 | 1934 | 0.510 |
Why?
|
| Health Resources | 1 | 2017 | 173 | 0.500 |
Why?
|
| Chelating Agents | 1 | 2016 | 130 | 0.500 |
Why?
|
| Protein Kinases | 4 | 2021 | 917 | 0.500 |
Why?
|
| DNA | 16 | 2017 | 3072 | 0.500 |
Why?
|
| Caspases, Effector | 1 | 2014 | 4 | 0.500 |
Why?
|
| Hydrogen Peroxide | 5 | 2018 | 225 | 0.500 |
Why?
|
| Quinolines | 2 | 2017 | 402 | 0.500 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2015 | 123 | 0.500 |
Why?
|
| B-Cell Activating Factor | 3 | 2015 | 26 | 0.500 |
Why?
|
| Fibroblasts | 6 | 2020 | 1669 | 0.490 |
Why?
|
| Deoxycytidine Kinase | 7 | 2013 | 27 | 0.490 |
Why?
|
| Monocytes | 1 | 2019 | 787 | 0.490 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 1260 | 0.490 |
Why?
|
| Mutation | 10 | 2024 | 15841 | 0.490 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2012 | 380 | 0.470 |
Why?
|
| Clinical Trials, Phase I as Topic | 8 | 2017 | 621 | 0.470 |
Why?
|
| Guanosine | 3 | 2010 | 26 | 0.470 |
Why?
|
| Lactams, Macrocyclic | 2 | 2011 | 94 | 0.460 |
Why?
|
| Harringtonines | 2 | 2014 | 93 | 0.460 |
Why?
|
| Aged | 53 | 2024 | 73160 | 0.460 |
Why?
|
| Leukemia, Lymphoid | 2 | 2005 | 291 | 0.460 |
Why?
|
| Benzoquinones | 2 | 2011 | 113 | 0.460 |
Why?
|
| Cladribine | 9 | 2013 | 253 | 0.450 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 97 | 0.450 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 386 | 0.450 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1734 | 0.450 |
Why?
|
| Deoxyadenine Nucleotides | 3 | 2008 | 29 | 0.450 |
Why?
|
| Drug Administration Schedule | 23 | 2018 | 3540 | 0.450 |
Why?
|
| Pyrroles | 3 | 2006 | 592 | 0.450 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 662 | 0.440 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2011 | 294 | 0.440 |
Why?
|
| Male | 65 | 2024 | 128412 | 0.440 |
Why?
|
| Cells, Cultured | 10 | 2017 | 5781 | 0.440 |
Why?
|
| Middle Aged | 59 | 2024 | 90016 | 0.440 |
Why?
|
| Nitrophenols | 3 | 2020 | 95 | 0.430 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2019 | 609 | 0.430 |
Why?
|
| DNA, Neoplasm | 8 | 2009 | 1961 | 0.430 |
Why?
|
| Boronic Acids | 4 | 2018 | 366 | 0.430 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 1293 | 0.420 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2009 | 593 | 0.420 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2016 | 1725 | 0.420 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2012 | 76 | 0.420 |
Why?
|
| Chemokine CXCL2 | 1 | 2012 | 35 | 0.410 |
Why?
|
| Biomedical Research | 3 | 2024 | 802 | 0.410 |
Why?
|
| Protein Stability | 2 | 2023 | 374 | 0.400 |
Why?
|
| Adult | 54 | 2022 | 81545 | 0.390 |
Why?
|
| Female | 60 | 2024 | 148467 | 0.390 |
Why?
|
| Medical Oncology | 3 | 2017 | 1462 | 0.390 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 203 | 0.390 |
Why?
|
| Thymine Nucleotides | 1 | 2010 | 19 | 0.380 |
Why?
|
| DNA Repair | 5 | 2013 | 1886 | 0.370 |
Why?
|
| Lymphoma | 4 | 2013 | 1514 | 0.370 |
Why?
|
| Immunoblotting | 9 | 2017 | 916 | 0.370 |
Why?
|
| Thymidine | 1 | 2010 | 168 | 0.370 |
Why?
|
| Neoplasm Proteins | 9 | 2014 | 3349 | 0.370 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2014 | 1144 | 0.360 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2008 | 211 | 0.360 |
Why?
|
| Blotting, Western | 9 | 2016 | 3648 | 0.360 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2017 | 530 | 0.350 |
Why?
|
| Oxygen Consumption | 3 | 2019 | 422 | 0.350 |
Why?
|
| Succinic Acid | 1 | 2010 | 28 | 0.350 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 193 | 0.350 |
Why?
|
| Fumarates | 1 | 2010 | 29 | 0.350 |
Why?
|
| Blast Crisis | 6 | 2012 | 587 | 0.350 |
Why?
|
| In Vitro Techniques | 8 | 2015 | 1744 | 0.350 |
Why?
|
| Jurkat Cells | 3 | 2020 | 319 | 0.340 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 319 | 0.340 |
Why?
|
| Prognosis | 15 | 2021 | 22456 | 0.340 |
Why?
|
| ATP Synthetase Complexes | 1 | 2009 | 5 | 0.340 |
Why?
|
| Down-Regulation | 4 | 2009 | 2109 | 0.340 |
Why?
|
| Infusions, Intravenous | 13 | 2006 | 1438 | 0.330 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 102 | 0.330 |
Why?
|
| Bone Marrow | 5 | 2019 | 2434 | 0.330 |
Why?
|
| Deoxyguanosine | 4 | 2007 | 32 | 0.330 |
Why?
|
| Clinical Trials as Topic | 15 | 2017 | 3862 | 0.330 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2017 | 686 | 0.330 |
Why?
|
| CD40 Ligand | 1 | 2009 | 130 | 0.330 |
Why?
|
| CD40 Antigens | 1 | 2009 | 107 | 0.320 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 39 | 0.320 |
Why?
|
| Embryo, Mammalian | 3 | 2017 | 757 | 0.310 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2019 | 1212 | 0.310 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 504 | 0.310 |
Why?
|
| Deoxyguanine Nucleotides | 4 | 2013 | 22 | 0.310 |
Why?
|
| Metabolic Networks and Pathways | 4 | 2019 | 337 | 0.310 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 474 | 0.310 |
Why?
|
| Cell Line | 8 | 2019 | 5435 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2017 | 1836 | 0.300 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2008 | 48 | 0.300 |
Why?
|
| Polyadenylation | 1 | 2008 | 65 | 0.300 |
Why?
|
| Chemokine CCL4 | 3 | 2017 | 68 | 0.300 |
Why?
|
| Chemokine CCL3 | 3 | 2017 | 65 | 0.290 |
Why?
|
| Receptor, Notch1 | 1 | 2009 | 220 | 0.290 |
Why?
|
| Substrate Specificity | 6 | 2009 | 582 | 0.290 |
Why?
|
| Cyclin E | 1 | 2009 | 278 | 0.290 |
Why?
|
| Enzyme Activation | 6 | 2015 | 1834 | 0.290 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2010 | 41 | 0.290 |
Why?
|
| Molecular Structure | 6 | 2010 | 536 | 0.280 |
Why?
|
| Nucleotides | 6 | 2023 | 174 | 0.280 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2006 | 26 | 0.280 |
Why?
|
| bcl-X Protein | 3 | 2017 | 199 | 0.280 |
Why?
|
| MicroRNAs | 3 | 2024 | 2906 | 0.280 |
Why?
|
| RNA, Ribosomal | 3 | 2003 | 94 | 0.280 |
Why?
|
| Antioxidants | 3 | 2020 | 521 | 0.270 |
Why?
|
| Gene Expression | 5 | 2017 | 3680 | 0.270 |
Why?
|
| Idarubicin | 3 | 2017 | 459 | 0.270 |
Why?
|
| Plant Proteins | 1 | 2006 | 133 | 0.260 |
Why?
|
| Kinetics | 10 | 2005 | 2246 | 0.260 |
Why?
|
| Salvage Therapy | 4 | 2011 | 2117 | 0.260 |
Why?
|
| Nucleosides | 5 | 2008 | 63 | 0.260 |
Why?
|
| Drugs, Investigational | 1 | 2006 | 130 | 0.260 |
Why?
|
| Cell Communication | 3 | 2017 | 515 | 0.250 |
Why?
|
| Uncoupling Agents | 2 | 2019 | 15 | 0.250 |
Why?
|
| DNA Replication | 6 | 1996 | 772 | 0.250 |
Why?
|
| RNA Polymerase II | 4 | 2010 | 184 | 0.250 |
Why?
|
| Intercalating Agents | 2 | 2017 | 32 | 0.250 |
Why?
|
| Leukemia, Myeloid | 5 | 2009 | 994 | 0.240 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2022 | 1068 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2019 | 3920 | 0.240 |
Why?
|
| Treatment Outcome | 25 | 2018 | 33819 | 0.240 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 30941 | 0.240 |
Why?
|
| Intracellular Space | 2 | 2017 | 78 | 0.230 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 5161 | 0.230 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2023 | 13 | 0.230 |
Why?
|
| Thiosemicarbazones | 1 | 2003 | 24 | 0.230 |
Why?
|
| Societies, Scientific | 2 | 2014 | 69 | 0.230 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 896 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 7 | 2018 | 1322 | 0.230 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2002 | 142 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 369 | 0.220 |
Why?
|
| Biomarkers | 4 | 2019 | 5105 | 0.220 |
Why?
|
| Biotransformation | 6 | 2002 | 98 | 0.220 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 3 | 2016 | 124 | 0.220 |
Why?
|
| Models, Chemical | 4 | 2009 | 183 | 0.210 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2002 | 104 | 0.210 |
Why?
|
| K562 Cells | 5 | 2012 | 345 | 0.210 |
Why?
|
| Chromatography, Affinity | 1 | 2002 | 145 | 0.210 |
Why?
|
| Time Factors | 14 | 2014 | 13110 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 4 | 2014 | 2399 | 0.210 |
Why?
|
| RNA Viruses | 1 | 2022 | 42 | 0.210 |
Why?
|
| Clinical Studies as Topic | 1 | 2022 | 18 | 0.210 |
Why?
|
| Mentoring | 1 | 2024 | 96 | 0.210 |
Why?
|
| Administration, Oral | 4 | 2021 | 1619 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 2 | 2008 | 3245 | 0.200 |
Why?
|
| Cell Growth Processes | 3 | 2013 | 339 | 0.200 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2020 | 128 | 0.200 |
Why?
|
| Base Sequence | 9 | 2017 | 5495 | 0.200 |
Why?
|
| Clone Cells | 1 | 2023 | 592 | 0.200 |
Why?
|
| Acute Disease | 6 | 2013 | 2515 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 1838 | 0.190 |
Why?
|
| Leukemia, T-Cell | 3 | 2009 | 90 | 0.190 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 224 | 0.190 |
Why?
|
| Bortezomib | 2 | 2015 | 553 | 0.190 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2001 | 10 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2008 | 770 | 0.190 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2001 | 54 | 0.190 |
Why?
|
| Pentostatin | 2 | 2002 | 121 | 0.190 |
Why?
|
| Pyridines | 2 | 2009 | 1311 | 0.190 |
Why?
|
| Protein Conformation | 3 | 2016 | 1280 | 0.180 |
Why?
|
| Remission Induction | 13 | 2022 | 3645 | 0.180 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2015 | 285 | 0.180 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 176 | 0.180 |
Why?
|
| Models, Biological | 5 | 2016 | 3225 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 7 | 2012 | 3145 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 248 | 0.180 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 2366 | 0.170 |
Why?
|
| Cell Division | 6 | 2008 | 2716 | 0.170 |
Why?
|
| Oxazoles | 2 | 2010 | 62 | 0.170 |
Why?
|
| Hydroxyurea | 2 | 1998 | 223 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 623 | 0.170 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 2214 | 0.170 |
Why?
|
| Immunologic Factors | 2 | 2019 | 670 | 0.170 |
Why?
|
| Cytosol | 3 | 2011 | 271 | 0.160 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2019 | 159 | 0.160 |
Why?
|
| Flavonoids | 4 | 2009 | 201 | 0.160 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2019 | 106 | 0.160 |
Why?
|
| DNA Polymerase I | 2 | 2002 | 30 | 0.160 |
Why?
|
| Melphalan | 2 | 2015 | 877 | 0.160 |
Why?
|
| Cytidine Triphosphate | 1 | 2018 | 8 | 0.160 |
Why?
|
| Protein Binding | 5 | 2016 | 3536 | 0.160 |
Why?
|
| Uridine Triphosphate | 1 | 1998 | 23 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2021 | 356 | 0.160 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10698 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 1997 | 1469 | 0.160 |
Why?
|
| HeLa Cells | 2 | 2021 | 1719 | 0.160 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 911 | 0.150 |
Why?
|
| Lysosomes | 1 | 2020 | 347 | 0.150 |
Why?
|
| Histones | 2 | 2020 | 1510 | 0.150 |
Why?
|
| Cell Count | 1 | 2019 | 524 | 0.150 |
Why?
|
| Recurrence | 11 | 2018 | 4880 | 0.150 |
Why?
|
| Drug Approval | 3 | 2014 | 178 | 0.150 |
Why?
|
| Indolequinones | 1 | 2017 | 4 | 0.150 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2017 | 15 | 0.150 |
Why?
|
| Ribonucleotides | 1 | 2017 | 55 | 0.150 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 6784 | 0.140 |
Why?
|
| Benzene Derivatives | 1 | 2017 | 27 | 0.140 |
Why?
|
| Enzyme Induction | 1 | 2017 | 262 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 1502 | 0.140 |
Why?
|
| Chemotaxis | 2 | 2015 | 142 | 0.140 |
Why?
|
| Glutamine | 1 | 2019 | 329 | 0.140 |
Why?
|
| DNA Polymerase II | 2 | 2002 | 59 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2010 | 1666 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 257 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 397 | 0.140 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 202 | 0.140 |
Why?
|
| Child | 16 | 2018 | 30380 | 0.140 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5836 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 5517 | 0.140 |
Why?
|
| International Agencies | 2 | 2014 | 106 | 0.140 |
Why?
|
| Leukocytes | 1 | 2019 | 424 | 0.140 |
Why?
|
| DNA Ligases | 1 | 1996 | 66 | 0.140 |
Why?
|
| Ubiquitinated Proteins | 1 | 2016 | 9 | 0.140 |
Why?
|
| Mice, SCID | 4 | 2019 | 1855 | 0.140 |
Why?
|
| Transcription Factor CHOP | 1 | 2016 | 24 | 0.140 |
Why?
|
| Triterpenes | 1 | 2016 | 68 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2020 | 1473 | 0.130 |
Why?
|
| HL-60 Cells | 2 | 2015 | 318 | 0.130 |
Why?
|
| Phosphoproteins | 2 | 2012 | 1229 | 0.130 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 718 | 0.130 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2016 | 163 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1994 | 426 | 0.130 |
Why?
|
| DNA Primers | 3 | 2009 | 1508 | 0.130 |
Why?
|
| Phosphonoacetic Acid | 1 | 2015 | 19 | 0.130 |
Why?
|
| Rats | 3 | 2002 | 6635 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 1152 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 879 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2018 | 2848 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2015 | 253 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2015 | 640 | 0.130 |
Why?
|
| Cyclin A | 1 | 2015 | 50 | 0.130 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 11761 | 0.130 |
Why?
|
| Thiazoles | 2 | 2010 | 729 | 0.130 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 435 | 0.130 |
Why?
|
| Hematologic Diseases | 2 | 1994 | 255 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2018 | 4327 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2012 | 1467 | 0.130 |
Why?
|
| Cell Nucleus | 1 | 2020 | 1742 | 0.120 |
Why?
|
| Aspartic Acid | 1 | 2015 | 136 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 594 | 0.120 |
Why?
|
| Protein Domains | 1 | 2016 | 324 | 0.120 |
Why?
|
| Young Adult | 11 | 2022 | 22054 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 486 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 704 | 0.120 |
Why?
|
| Caspase 9 | 3 | 2011 | 191 | 0.120 |
Why?
|
| Thiourea | 1 | 2013 | 20 | 0.120 |
Why?
|
| Deoxyribonucleotides | 2 | 1991 | 22 | 0.120 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 1994 | 286 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2016 | 487 | 0.110 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2013 | 29 | 0.110 |
Why?
|
| S Phase | 3 | 2002 | 290 | 0.110 |
Why?
|
| Cross-Linking Reagents | 1 | 2014 | 167 | 0.110 |
Why?
|
| Indoles | 1 | 2019 | 1035 | 0.110 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 2 | 2011 | 42 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 887 | 0.110 |
Why?
|
| Protein Precursors | 1 | 2014 | 250 | 0.110 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 238 | 0.110 |
Why?
|
| Adolescent | 16 | 2022 | 32556 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 5233 | 0.110 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2125 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 603 | 0.110 |
Why?
|
| Cyclin D1 | 2 | 2012 | 589 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2016 | 1567 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 2560 | 0.110 |
Why?
|
| Metallocenes | 1 | 2012 | 3 | 0.110 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2012 | 26 | 0.110 |
Why?
|
| Ferrous Compounds | 1 | 2012 | 14 | 0.100 |
Why?
|
| Child, Preschool | 10 | 2018 | 16957 | 0.100 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2008 | 318 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 335 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2013 | 282 | 0.100 |
Why?
|
| Adenosine Kinase | 2 | 2002 | 9 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 7461 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1408 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 10349 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 7936 | 0.100 |
Why?
|
| Mechlorethamine | 1 | 2011 | 55 | 0.100 |
Why?
|
| Boron Compounds | 1 | 2012 | 69 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 6170 | 0.100 |
Why?
|
| Leukemia, Experimental | 2 | 2006 | 83 | 0.100 |
Why?
|
| Leukemic Infiltration | 1 | 2011 | 73 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2024 | 1885 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 272 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 161 | 0.100 |
Why?
|
| Transfection | 4 | 2021 | 3169 | 0.100 |
Why?
|
| Thalidomide | 1 | 2015 | 600 | 0.100 |
Why?
|
| raf Kinases | 1 | 2011 | 81 | 0.100 |
Why?
|
| Apoptosomes | 1 | 2011 | 12 | 0.100 |
Why?
|
| 5'-Nucleotidase | 1 | 2011 | 63 | 0.090 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 2 | 2010 | 22 | 0.090 |
Why?
|
| Cytochromes c | 2 | 2011 | 117 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2013 | 264 | 0.090 |
Why?
|
| Oligomycins | 1 | 2010 | 10 | 0.090 |
Why?
|
| Imatinib Mesylate | 2 | 2012 | 1691 | 0.090 |
Why?
|
| Disease Progression | 2 | 2013 | 6890 | 0.090 |
Why?
|
| Cell Movement | 1 | 2017 | 2500 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2021 | 3231 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2015 | 1506 | 0.090 |
Why?
|
| Toxins, Biological | 1 | 2010 | 71 | 0.090 |
Why?
|
| Cytokines | 1 | 2019 | 2836 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2020 | 4190 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 13976 | 0.080 |
Why?
|
| Citric Acid Cycle | 1 | 2010 | 94 | 0.080 |
Why?
|
| Poly A | 1 | 2009 | 96 | 0.080 |
Why?
|
| Halogenation | 1 | 2009 | 14 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2015 | 636 | 0.080 |
Why?
|
| Research Design | 1 | 2017 | 1568 | 0.080 |
Why?
|
| Oxazines | 1 | 2009 | 41 | 0.080 |
Why?
|
| Age Factors | 2 | 2016 | 5492 | 0.080 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2009 | 44 | 0.080 |
Why?
|
| Nitrendipine | 1 | 1988 | 3 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2007 | 956 | 0.080 |
Why?
|
| Dactinomycin | 1 | 2009 | 163 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2009 | 237 | 0.080 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2009 | 87 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2018 | 2465 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2012 | 5324 | 0.080 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2008 | 24 | 0.080 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2008 | 21 | 0.080 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 135 | 0.080 |
Why?
|
| Survival Rate | 8 | 2021 | 12516 | 0.080 |
Why?
|
| Caspase Inhibitors | 1 | 2008 | 98 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 59 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2008 | 95 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 9042 | 0.080 |
Why?
|
| Molecular Mimicry | 1 | 2008 | 71 | 0.080 |
Why?
|
| Nimodipine | 1 | 1987 | 12 | 0.080 |
Why?
|
| Core Binding Factors | 1 | 2008 | 113 | 0.080 |
Why?
|
| Calpain | 1 | 2008 | 72 | 0.080 |
Why?
|
| Biological Availability | 2 | 2002 | 226 | 0.080 |
Why?
|
| Receptors, Opioid | 1 | 1987 | 40 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 98 | 0.080 |
Why?
|
| RNA, Catalytic | 1 | 2007 | 39 | 0.080 |
Why?
|
| Superoxides | 1 | 2008 | 222 | 0.080 |
Why?
|
| Cattle | 1 | 2009 | 846 | 0.070 |
Why?
|
| Biosynthetic Pathways | 1 | 2007 | 48 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2008 | 627 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2008 | 163 | 0.070 |
Why?
|
| G2 Phase | 2 | 2002 | 218 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 843 | 0.070 |
Why?
|
| Acetylcysteine | 1 | 2008 | 139 | 0.070 |
Why?
|
| Introns | 1 | 2008 | 459 | 0.070 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 512 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 1987 | 114 | 0.070 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 323 | 0.070 |
Why?
|
| Leukemia, B-Cell | 2 | 1998 | 114 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 320 | 0.070 |
Why?
|
| Dipyridamole | 2 | 2022 | 41 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2009 | 1758 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 1004 | 0.070 |
Why?
|
| Esters | 2 | 2018 | 49 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4967 | 0.070 |
Why?
|
| Cell-Free System | 2 | 2006 | 175 | 0.070 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 2003 | 48 | 0.070 |
Why?
|
| Ion Channels | 1 | 1987 | 241 | 0.070 |
Why?
|
| Marketing | 1 | 2006 | 16 | 0.070 |
Why?
|
| Infant | 5 | 2018 | 13891 | 0.070 |
Why?
|
| Mitoxantrone | 2 | 1996 | 228 | 0.070 |
Why?
|
| Metformin | 1 | 2010 | 395 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2004 | 738 | 0.060 |
Why?
|
| Staurosporine | 1 | 2005 | 149 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6027 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 16186 | 0.060 |
Why?
|
| Oncogenes | 1 | 2008 | 700 | 0.060 |
Why?
|
| G1 Phase | 2 | 1999 | 306 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 623 | 0.060 |
Why?
|
| Cell Nucleolus | 2 | 1983 | 102 | 0.060 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2005 | 86 | 0.060 |
Why?
|
| Disease-Free Survival | 5 | 2018 | 10249 | 0.060 |
Why?
|
| Spinal Cord | 1 | 1988 | 726 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 1080 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 1146 | 0.060 |
Why?
|
| DNA Fragmentation | 2 | 2007 | 208 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 948 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 255 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2007 | 706 | 0.060 |
Why?
|
| DCMP Deaminase | 2 | 1996 | 10 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 279 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 1733 | 0.060 |
Why?
|
| Cricetinae | 2 | 1995 | 792 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2007 | 439 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 485 | 0.060 |
Why?
|
| Neutropenia | 2 | 2019 | 1001 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 300 | 0.060 |
Why?
|
| Guanosine Monophosphate | 1 | 2003 | 6 | 0.060 |
Why?
|
| Paecilomyces | 1 | 2003 | 8 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 349 | 0.060 |
Why?
|
| Antigens, CD19 | 1 | 2006 | 584 | 0.060 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 25 | 0.050 |
Why?
|
| Glucose | 1 | 2009 | 1249 | 0.050 |
Why?
|
| Deoxycytosine Nucleotides | 2 | 1994 | 32 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2490 | 0.050 |
Why?
|
| Chemical Precipitation | 1 | 2002 | 27 | 0.050 |
Why?
|
| Multigene Family | 1 | 2024 | 459 | 0.050 |
Why?
|
| Quinaldines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 2412 | 0.050 |
Why?
|
| Faculty | 1 | 2024 | 132 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 2350 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2003 | 245 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 155 | 0.050 |
Why?
|
| Peritonitis | 1 | 2003 | 100 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 1011 | 0.050 |
Why?
|
| Chlorambucil | 1 | 2002 | 26 | 0.050 |
Why?
|
| Nucleoside Deaminases | 1 | 2002 | 45 | 0.050 |
Why?
|
| Inosine | 1 | 2002 | 42 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 206 | 0.050 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2022 | 46 | 0.050 |
Why?
|
| Phenotype | 3 | 2011 | 6464 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2002 | 113 | 0.050 |
Why?
|
| United States | 2 | 2024 | 15981 | 0.050 |
Why?
|
| Half-Life | 3 | 2004 | 269 | 0.050 |
Why?
|
| Sex Chromosomes | 1 | 1982 | 43 | 0.050 |
Why?
|
| Antimalarials | 1 | 2002 | 54 | 0.050 |
Why?
|
| Safety | 1 | 2003 | 466 | 0.050 |
Why?
|
| fas Receptor | 1 | 2003 | 200 | 0.050 |
Why?
|
| Software | 1 | 2009 | 1361 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2002 | 723 | 0.050 |
Why?
|
| Y Chromosome | 1 | 1982 | 81 | 0.050 |
Why?
|
| Mentors | 1 | 2024 | 203 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1599 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 3142 | 0.050 |
Why?
|
| Risk Factors | 3 | 2013 | 17820 | 0.050 |
Why?
|
| Fatigue | 2 | 2018 | 1277 | 0.050 |
Why?
|
| Protozoan Proteins | 1 | 2002 | 118 | 0.050 |
Why?
|
| Species Specificity | 1 | 2002 | 809 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2000 | 75 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2011 | 201 | 0.050 |
Why?
|
| Proteins | 2 | 2006 | 2047 | 0.050 |
Why?
|
| Inflammation | 1 | 2010 | 2526 | 0.040 |
Why?
|
| Aphidicolin | 1 | 1999 | 30 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2019 | 4360 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 446 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2007 | 1732 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 15247 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2003 | 624 | 0.040 |
Why?
|
| Telomerase | 1 | 2003 | 533 | 0.040 |
Why?
|
| Calibration | 1 | 2000 | 346 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2007 | 324 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 255 | 0.040 |
Why?
|
| Mycoses | 1 | 2003 | 396 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2021 | 2314 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 1998 | 565 | 0.040 |
Why?
|
| Methylation | 2 | 2011 | 626 | 0.040 |
Why?
|
| Drosophila melanogaster | 2 | 1983 | 865 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 6248 | 0.040 |
Why?
|
| Virus Replication | 1 | 2022 | 761 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 618 | 0.040 |
Why?
|
| Maximum Allowable Concentration | 1 | 1998 | 11 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1999 | 123 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 103 | 0.040 |
Why?
|
| Glutaminase | 1 | 2019 | 71 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2011 | 5494 | 0.040 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2001 | 303 | 0.040 |
Why?
|
| Genomics | 1 | 2009 | 2817 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 1107 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 4983 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 5042 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 4371 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2000 | 5185 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 914 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 88 | 0.040 |
Why?
|
| Base Composition | 1 | 1997 | 93 | 0.040 |
Why?
|
| Templates, Genetic | 1 | 1997 | 127 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 2250 | 0.040 |
Why?
|
| Deoxycytidine Monophosphate | 1 | 1996 | 5 | 0.040 |
Why?
|
| Biomimetics | 1 | 2017 | 34 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 4067 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 2346 | 0.040 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2016 | 10 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 2 | 2003 | 949 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2010 | 265 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2011 | 9430 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2012 | 9305 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 960 | 0.030 |
Why?
|
| Exodeoxyribonucleases | 1 | 1996 | 108 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2009 | 1045 | 0.030 |
Why?
|
| Peptide Chain Elongation, Translational | 1 | 1995 | 7 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 671 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3395 | 0.030 |
Why?
|
| Drug Evaluation | 3 | 1993 | 435 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2009 | 906 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1996 | 126 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 1995 | 85 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1996 | 199 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 1255 | 0.030 |
Why?
|
| Daunorubicin | 2 | 2009 | 313 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 7216 | 0.030 |
Why?
|
| CHO Cells | 1 | 1995 | 323 | 0.030 |
Why?
|
| Genome, Human | 1 | 2003 | 1834 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 2474 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2005 | 308 | 0.030 |
Why?
|
| Biological Transport | 2 | 2007 | 647 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 326 | 0.030 |
Why?
|
| HapMap Project | 1 | 2013 | 13 | 0.030 |
Why?
|
| Etoposide | 2 | 2009 | 905 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 1368 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 1486 | 0.030 |
Why?
|
| Hemodialysis Solutions | 1 | 1992 | 7 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 505 | 0.030 |
Why?
|
| Hypophosphatemia | 1 | 1992 | 27 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1057 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2012 | 72 | 0.030 |
Why?
|
| Phosphorus | 1 | 1992 | 70 | 0.030 |
Why?
|
| Intracellular Fluid | 1 | 1992 | 49 | 0.030 |
Why?
|
| Metaphase | 1 | 1992 | 124 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 1991 | 26 | 0.020 |
Why?
|
| Dialysis Solutions | 1 | 1991 | 12 | 0.020 |
Why?
|
| Sterilization | 1 | 1991 | 13 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1654 | 0.020 |
Why?
|
| Rituximab | 1 | 2017 | 1589 | 0.020 |
Why?
|
| Drug Interactions | 2 | 1992 | 585 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 749 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1991 | 114 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2011 | 400 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2012 | 235 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2017 | 1328 | 0.020 |
Why?
|
| Deamination | 1 | 1990 | 13 | 0.020 |
Why?
|
| ErbB Receptors | 2 | 2012 | 2379 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1991 | 233 | 0.020 |
Why?
|
| RNA, Small Nuclear | 1 | 2010 | 55 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 596 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 462 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1996 | 1443 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1070 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2009 | 28 | 0.020 |
Why?
|
| Mutagens | 1 | 1990 | 183 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 178 | 0.020 |
Why?
|
| Phosphotransferases | 1 | 1989 | 84 | 0.020 |
Why?
|
| Chloroquine | 1 | 2009 | 62 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2009 | 62 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 451 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1991 | 125 | 0.020 |
Why?
|
| Syk Kinase | 1 | 2009 | 65 | 0.020 |
Why?
|
| LLC-PK1 Cells | 1 | 2009 | 9 | 0.020 |
Why?
|
| Quinacrine | 1 | 1988 | 5 | 0.020 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1988 | 10 | 0.020 |
Why?
|
| Trifluoperazine | 1 | 1988 | 8 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 113 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 1065 | 0.020 |
Why?
|
| Nifedipine | 1 | 1988 | 26 | 0.020 |
Why?
|
| Verapamil | 1 | 1988 | 84 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 483 | 0.020 |
Why?
|
| Pain | 1 | 2017 | 1695 | 0.020 |
Why?
|
| Asparaginase | 1 | 2009 | 185 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 631 | 0.020 |
Why?
|
| Benzomorphans | 1 | 1987 | 1 | 0.020 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1987 | 2 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 874 | 0.020 |
Why?
|
| Dioxolanes | 1 | 2008 | 51 | 0.020 |
Why?
|
| Receptors, Opioid, kappa | 1 | 1987 | 33 | 0.020 |
Why?
|
| Fibronectins | 1 | 2008 | 211 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1987 | 339 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1987 | 171 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1379 | 0.020 |
Why?
|
| Biometry | 1 | 2009 | 241 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1613 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2008 | 202 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 718 | 0.020 |
Why?
|
| Cytosine | 1 | 2008 | 156 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 783 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 136 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 584 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2009 | 227 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2005 | 40 | 0.020 |
Why?
|
| Morphine | 1 | 1987 | 332 | 0.020 |
Why?
|
| Immunotoxins | 1 | 2006 | 120 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 104 | 0.020 |
Why?
|
| India | 1 | 2006 | 314 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2010 | 6832 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1992 | 921 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 250 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 815 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 169 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 2670 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 4787 | 0.020 |
Why?
|
| Polyphosphates | 1 | 2004 | 16 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 241 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 860 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2006 | 296 | 0.010 |
Why?
|
| Lysine | 1 | 2006 | 428 | 0.010 |
Why?
|
| Multiprotein Complexes | 1 | 2006 | 388 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 5188 | 0.010 |
Why?
|
| Tritium | 1 | 2003 | 268 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2003 | 123 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 1583 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2011 | 2087 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Karyotyping | 1 | 2004 | 1064 | 0.010 |
Why?
|
| Flucytosine | 1 | 2002 | 33 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 2002 | 43 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2002 | 150 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 382 | 0.010 |
Why?
|
| Pupa | 1 | 1982 | 25 | 0.010 |
Why?
|
| Ovum | 1 | 1982 | 37 | 0.010 |
Why?
|
| Stem Cells | 1 | 2009 | 1230 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 2306 | 0.010 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2002 | 123 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 1982 | 131 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 615 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 4331 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2002 | 457 | 0.010 |
Why?
|
| Larva | 1 | 1982 | 292 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1982 | 632 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2002 | 634 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1617 | 0.010 |
Why?
|
| Phosphates | 1 | 2001 | 193 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 5086 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4385 | 0.010 |
Why?
|
| Telomere | 1 | 2003 | 534 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 1522 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 1076 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2006 | 2736 | 0.010 |
Why?
|
| Brain | 1 | 1988 | 4256 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 13350 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2001 | 920 | 0.010 |
Why?
|
| Alkylating Agents | 1 | 1994 | 82 | 0.010 |
Why?
|
| Conjunctivitis | 1 | 1993 | 28 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 3124 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 2493 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1993 | 187 | 0.010 |
Why?
|
| Micropore Filters | 1 | 1991 | 11 | 0.010 |
Why?
|
| Nylons | 1 | 1991 | 20 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1994 | 366 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 7809 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 4182 | 0.010 |
Why?
|
| Sarcoma | 1 | 2001 | 1840 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 6982 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1993 | 292 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1994 | 567 | 0.010 |
Why?
|
| Colitis | 1 | 1993 | 344 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1993 | 408 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1993 | 1773 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1983 | 162 | 0.000 |
Why?
|
| X Chromosome | 1 | 1983 | 399 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1983 | 472 | 0.000 |
Why?
|
| Genes | 1 | 1983 | 611 | 0.000 |
Why?
|